DMD Simcyp - the leader in IVIVE

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

Drug Metabolism and Disposition Fast Forward
First published on February 14, 2008; DOI: 10.1124/dmd.107.019349

0090-9556/08/3605-955-962$20.00
DMD 36:955-962, 2008

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.107.019349v1
36/5/955    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Google Scholar
Right arrow Articles by Löfgren, S.
Right arrow Articles by Ingelman-Sundberg, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Löfgren, S.
Right arrow Articles by Ingelman-Sundberg, M.

Generation of Mice Transgenic for Human CYP2C18 and CYP2C19: Characterization of the Sexually Dimorphic Gene and Enzyme Expression

Susanne Löfgren, R. Michael Baldwin, Masahiro Hiratsuka1, Annelie Lindqvist2, Anne Carlberg, Sarah C. Sim, Meint Schülke, Michael Snait, Anne Edenro, Ronny Fransson-Steen, Ylva Terelius2, and Magnus Ingelman-Sundberg

Department of Physiology and Pharmacology, Section of Pharmacogenetics, Karolinska Institutet, Stockholm, Sweden (R.M.B., M.H., A.C., S.C.S., M.I.-S.); Safety Assessment (S.L., R.F.-S.) and Research Drug Metabolism and Pharmacokinetics (A.L., Y.T.), AstraZeneca Research and Development, Södertälje, Sweden; AstraZeneca Transgenics and Comparative Genomics, AstraZeneca Research and Development, Mölndal, Sweden (M.Sc., A.E.); and Cambridge Antibody Technology, Milstein Building Granta Park, Cambridge, United Kingdom (M.Sn.)

CYP2C19 is an important enzyme for human drug metabolism, and it also participates in the metabolism of endogenous substrates, whereas the CYP2C18 enzyme is not expressed in human liver despite high mRNA expression. Mice transgenic for the human CYP2C18 and CYP2C19 genes were generated. Quantitative mRNA analysis showed CYP2C18 and CYP2C19 transcripts in liver, kidneys, and heart to be expressed in a sexually dimorphic manner, with male mice having 2- to 100-fold higher levels. Transcript levels in the small intestine were somewhat higher than liver but were similar in both sexes. Transgene mRNA expression was much lower in lung and brain and least in the heart. Immunoblotting using an antipeptide antiserum, reactive with human CYP2Cs and mouse CYP2C70, revealed increased immunoreactive protein in liver microsomes from heterozygous transgenic male mice and a concomitant increase in 5'-hydroxylation of R-omeprazole and S-mephenytoin intrinsic clearance, consistent with CYP2C19 overexpression. A CYP2C18-specific antiserum showed that this enzyme was not expressed in livers or kidneys from heterozygous transgenic mice, but the antiserum had high affinity for recombinant CYP2C18 expressed in COS-7 cells. It is concluded that 1) both the CYP2C18 and CYP2C19 genes are subject to sexually dimorphic regulation in murine liver, kidney, and heart; 2) the CYP2C18 protein is not expressed in murine liver or kidney despite high levels of the corresponding mRNA; and 3) this transgenic model may be suitable for studying sex-dependent regulation of the human CYP2C genes and possibly serve as an in vivo model for CYP2C19-dependent drug metabolism.

Address correspondence to: R. Michael Baldwin, Section of Pharmacogenetics, Department of Physiology and Pharmacology, Karolinska Institutet, Nanna Svartz väg 2, SE-17177 Stockholm, Sweden. E-mail: mike.baldwin{at}ki.se






Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2008 by the American Society for Pharmacology and Experimental Therapeutics.